COVID-19 in cancer patients

Leave a comment
Click any image to enlarge
Authors:
Sponsorship Statement: Novo Nordisk has provided a grant to Medinews (Cardiology) Ltd to support the cost of the production of this bulletin. Novo Nordisk has had no influence or control over the content of the bulletin.

Cancer-associated thrombosis

COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. Many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice and dosing of antithrombotic therapy including direct-acting oral anticoagulants (DOACs).

To address this urgent need, the International Society for Thrombosis and Haemostasis (ISTH) is providing open access to its COVID-19 resource page via the ISTH Academy, as well as making all content from the ISTH Academy freely accessible. To access all ISTH content, simply visit academy.isth.org and sign in with your ISTH log-in or create a free ISTH Academy account to get started.

On the ISTH Academy, you can access the latest education and resources from experts in the field around the world. In addition to courses on topics like venous thrombosis and cancer-associated thrombosis, you can also access past meeting presentations, posters, webinars and more.

The ISTH Academy also now offers unlimited access to articles from the Journal of Thrombosis and Haemostasis (JTH) and Research and Practice in Thrombosis and Haemostasis (RPTH). The COVID-19 page will continue to be frequently updated. Visit the open access COVID-19 resource page here. https://academy.isth.org/isth/#!*menu=8*browseby=8*sortby=2*label=19794

COVID-19 Bulletin 1:

COVID-19 and care of the elderly
COVID-19 and diabetes
COVID-19 and heart failure
COVID-19 and primary care
COVID-19 and cardiovascular disease
COVID-19 and respiratory medicine
Round up of COVID-19 e-learning, apps and websites

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT